공시 • Jun 21
Light AI Inc. announced that it has received CAD 5 million in funding On June 19, 2026, Light AI Inc. closed the transaction. 공시 • Jun 16
Light Ai Announces Company-Funded Field Study for Quickscan Strep A Platform in New Zealand Light AI Inc. announced a company-funded field study in New Zealand for the deployment and evaluation of the Company's QuickScan Strep A software platform in community and school-based healthcare settings. The field study is being conducted in collaboration with New Zealand healthcare stakeholders, including the National Hauora Coalition, and is designed to evaluate real-world implementation, workflow integration, accessibility, and commercial readiness of Light AI's QuickScan Strep A software application for point-of-care screening and clinical decision support relating to pharyngitis and suspected Group A Streptococcus infections. In pre-FDA validation studies, Light AI's algorithm demonstrated remarkable accuracy in differentiating between viral and bacterial pharyngitis, specifically targeting Group A Streptococcus. The algorithm achieved a 96.57% accuracy rate and attained a Negative Predictive Value of 100%, indicating its high reliability in confirming the absence of Streptococcus A infection. Viral and GAS pharyngitis affects over 600 million people annually worldwide. If left untreated, GAS pharyngitis can lead to serious complications such as Rheumatic Heart Disease, which imposes a global economic burden exceeding $1 trillion annually. Light AI QuickScan is a technology platform which represents the next generation of patient management: it applies AI algorithms to compatible smart device images, starting with images of Strep A and anticipated expansion with other medical conditions, to identify the disease in seconds. Its patented, app-based solution requires no swabs, lab tests or proprietary hardware of any kind as its computing platform includes the 4.5 billion smartphones that exist in the world today. 공시 • Jun 04
Light AI Initiates FDA Pivotal Clinical Trial for QuickScan Strep a Software as a Medical Device Light AI Inc. has received ethics committee approval to commence the pivotal clinical trial intended to generate clinical evidence to support a future submission to the U.S. Food and Drug Administration for potential marketing authorization of QuickScan Strep A as a Class II medical device. The study protocol and design are informed by prior regulatory interactions, including pre-submission feedback received by the Company during its 2024 FDA Q-Sub process. QuickScan Strep A is being developed as a smartphone-enabled software platform intended to analyze throat images and provide an AI-supported assessment for suspected Strep A infection. The software remains investigational and has not been cleared or approved by the FDA or other regulatory authorities for commercial diagnostic use. The pivotal study is expected to enroll participants presenting with symptoms consistent with pharyngitis and is designed to compare the diagnostic performance of QuickScan Strep A against throat culture, an established clinical reference standard. Predefined study endpoints include diagnostic outcome measures, usability assessments, and patient management-related measures intended to support evaluation of software performance and a future FDA submission. Strep A pharyngitis is a common condition evaluated across primary care, urgent care, pediatric, pharmacy and community healthcare settings. Subject to successful clinical validation, regulatory authorization and commercial adoption, Light AI believes there may be future opportunities for software-enabled assessment technologies to support healthcare delivery and patient management pathways. The Company expects to provide updates regarding study progress, enrollment milestones, and timing considerations as appropriate and in accordance with applicable securities disclosure obligations. 공시 • Jun 02
Light AI Inc., Annual General Meeting, Jul 22, 2026 Light AI Inc., Annual General Meeting, Jul 22, 2026. Location: british columbia, vancouver Canada 공시 • May 22
Light AI Inc. announced that it expects to receive CAD 5 million in funding Light AI Inc. announced a private placement with MV Capital LP to issue 5,000 secured convertible debenture units at an issue price of CAD 1,000 for the proceeds of CAD 5,000,000 on May 21, 2026. Each Unit will comprise of (i) a 12.0% secured convertible debenture of the Company in the principal amount equal to CAD 1,000 (each, a "Convertible Debenture") with interest compounded quarterly and payable on the earlier of the Maturity Date (as defined hereafter), prepayment or conversion and maturing 24 months from the closing of the Financing (the "Maturity Date"), and (ii) 8,000 common share purchase warrants (each, a "Warrant"), each Warrant being exercisable for a period of 36 months following the closing of the Financing (the "Closing Date") to purchase one common share of the Company (each, a "Warrant Share") at an exercise price of CAD 0.25 per Warrant Share. The Financing is expected to close on or around June 19, 2026, and is subject to certain closing conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Exchange. 